Table III.
Baseline vital signs and biomarkers
| Discontinuation of RAAS inhibitor (N = 21) | Continuation of RAAS inhibitor (N = 25) | |
|---|---|---|
| Heart rate, BPM (SD) | 77.7 (10.2) | 75.0 (11.4) |
| Resting systolic blood pressure, mmHg (SD) | 136.7 (17.0) | 135.7 (19.2) |
| Resting diastolic blood pressure, mmHg (SD) | 71.0 (11.8) | 71.6 (9.6) |
| Resting respiratory rate, respirations/minute, median (Q1, Q3)* | 20 (20, 20) | 20 (18, 20) n = 24 |
| Serum Hemoglobin, g/L (SD) | 12.2 (1.8) | 12.6 (2.0) |
| Serum Sodium, mmol/L (SD) | 137.8 (3.5) | 137.0 (4.6) |
| Serum Potassium, mmol/L (SD) | 4.2 (0.5) | 4.1 (0.5) |
| Blood Urea Nitrogen, mmol/L, median (Q1, Q3)* | 7.5 (6.4, 9.7) | 7.4 (4.8, 10.5) |
| Serum Glucose, mmol/L, median (Q1, Q3)* | 5.9 (5.0, 8.8) | 7.0 (4.9, 9.3) |
| C-reactive protein, mg/L, median (Q1, Q3)* | 37.5 (15.1, 65.9) | 32.7 (16.8, 91.4) |
| Lymphocyte count x 109, median (Q1, Q3)* | 0.87 (0.74, 1.23) | 1.11 (0.57, 1.30) |
| High-sensitivity Troponin I ng/L, median (Q1, Q3)* | 11.0 (7.9, 22.2) | 9.9 (7.4, 19.2) |
| Natriuretic Peptides BNP, pg/mL, median (Q1, Q3)* | 132.5 (47, 249.5) | 92.0 (60.0, 152.0) |
| eGFR, mL/min/1.73 m2, median (Q1, Q3)* | 92.5 (58.0, 101.6) | 60.9 (47.8, 95.8) |
BNP, brain natriuretic peptide; BPM, beats per minute; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin aldosterone system; SD, standard deviation. Q1, 25th percentile; Q3, 75th percentile.
⁎
Data are reported as median (Q1, Q3). Group difference is evaluated using Wilcoxon rank-sum test and no differences in baseline characteristics were identified. Standard range values are as follows: Blood urea nitrogen 2.1-8.5 mmol/L; glucose 3.9-11.0 mmol/L; C-reactive protein 0-5 mg/L; lymphocyte count 1.0-4.80 × 109; High-sensitivity Troponin I </= 17.5 ng/L; BNP < 100 pg/mL.